Dexco executives sign off on interim financial statements for quarter ended June 30, 2026
Reuters2026/08/21 22:14- Dexco executive officers met Aug. 5, 2026 to resolve on interim financial statements for the quarter ended June 30, 2026.
- Board resolved it had reviewed, discussed, and agreed with the interim individual and consolidated accounting information for the period.
- Board also resolved it agreed with Ernst & Young’s review report on the quarterly information, which concluded no material departures from NBC TG 21 and IAS 34.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Report: Anthropic’s prospectus may list U.S. public resistance to AI as a risk factor
Anthropic, with a valuation potentially as high as $2 trillion, is preparing for an IPO but faces a challenging public opinion backlash—a Gallup poll reveals that 70% of Americans oppose the construction of AI data centers in their communities. Amid the midterm elections, politicians from both parties are responding to voter sentiment, with a data center restriction bill recently enacted in Pennsylvania. According to media reports, for AI companies whose revenue is tied to computing power, this wave of public resistance may be listed as a key risk factor in their IPO prospectus.
Quantum BioPharma grants 572,500 stock options at C$ 4.8 each
Fleury liquidates BRL 1.83 billion unsecured debenture offering
Crypto prices
More
